Amyloid-β: a potential link between epilepsy and cognitive decline

[1]  Arjune Sen,et al.  Pathological brain ageing in epilepsy and dementia: two sides of the same coin? , 2021, Brain : a journal of neurology.

[2]  C. Hsiung,et al.  Late-onset epilepsy and subsequent increased risk of dementia. , 2021, Aging.

[3]  C. McDonald,et al.  Atrophy and cognitive profiles in older adults with temporal lobe epilepsy are similar to mild cognitive impairment. , 2020, Brain : a journal of neurology.

[4]  M. Husain,et al.  Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer’s Disease , 2020, International journal of molecular sciences.

[5]  M. Albert,et al.  Dementia in late-onset epilepsy , 2020, Neurology.

[6]  Dan J Stein,et al.  Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[7]  L. Mucke,et al.  Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer’s disease mutations but not by inhibition of BACE1 , 2020, Molecular Neurodegeneration.

[8]  Ravensara S. Travillian,et al.  Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, The Lancet.

[9]  B. Hyman,et al.  Synergy between amyloid-β and tau in Alzheimer’s disease , 2020, Nature Neuroscience.

[10]  B. Strooper,et al.  Tipping the Scales: Peptide-Dependent Dysregulation of Neural Circuit Dynamics in Alzheimer’s Disease , 2020, Neuron.

[11]  M. T. Pascarelli,et al.  Late-Onset Epilepsy With Unknown Etiology: A Pilot Study on Neuropsychological Profile, Cerebrospinal Fluid Biomarkers, and Quantitative EEG Characteristics , 2020, Frontiers in Neurology.

[12]  K. Yaffe,et al.  Association of Late-Onset Unprovoked Seizures of Unknown Etiology With the Risk of Developing Dementia in Older Veterans. , 2020, JAMA neurology.

[13]  E. Perucca,et al.  Time to Start Calling Things by Their Own Names? The Case for Antiseizure Medicines , 2020, Epilepsy currents.

[14]  P. Kwan,et al.  Antiepileptic drugs are not independently associated with cognitive dysfunction , 2020, Neurology.

[15]  Arjune Sen,et al.  Epilepsy in older people , 2020, The Lancet.

[16]  Arjune Sen,et al.  Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review , 2020, Epilepsy & Behavior.

[17]  T. Lucas,et al.  Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy. , 2019, Brain : a journal of neurology.

[18]  S. Lovestone,et al.  Aiding the discovery of new treatments for dementia by uncovering unknown benefits of existing medications , 2019, Alzheimer's & dementia.

[19]  C. Jack,et al.  Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia , 2019, JAMA network open.

[20]  L. Goldstein,et al.  Amyloid-β-independent regulators of tau pathology in Alzheimer disease , 2019, Nature Reviews Neuroscience.

[21]  H. Tanila,et al.  Characterization of Epileptic Spiking Associated With Brain Amyloidosis in APP/PS1 Mice , 2019, Front. Neurol..

[22]  P. Calabresi,et al.  Cognitive performances in patients affected by late-onset epilepsy with unknown etiology: A 12-month follow-up study , 2019, Epilepsy & Behavior.

[23]  J. Herms,et al.  Long-term dynamics of aberrant neuronal activity in Alzheimer’s disease , 2019, bioRxiv.

[24]  P. Calabresi,et al.  Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences , 2019, Current neuropharmacology.

[25]  David T. Jones,et al.  The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes , 2019, Brain : a journal of neurology.

[26]  P. Pennell,et al.  Late-onset unexplained epilepsy: What are we missing? , 2019, Epilepsy & Behavior.

[27]  A. Konnerth,et al.  A vicious cycle of β amyloid–dependent neuronal hyperactivation , 2019, Science.

[28]  F. Peña-Ortega,et al.  Single amyloid‐beta injection exacerbates 4‐aminopyridine‐induced seizures and changes synaptic coupling in the hippocampus , 2019, Hippocampus.

[29]  Philip S. Insel,et al.  β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly , 2019, Scientific Reports.

[30]  D. Selkoe.  Alzheimer disease and aducanumab: adjusting our approach , 2019, Nature Reviews Neurology.

[31]  G. Gore,et al.  The medical treatment of epilepsy in the elderly: A systematic review and meta‐analysis , 2019, Epilepsia.

[32]  P. Calabresi,et al.  Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events , 2019, Journal of Neurology.

[33]  Keith A. Johnson,et al.  Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease , 2019, JAMA neurology.

[34]  S. Gauthier,et al.  Diagnostic Approach of Early-Onset Dementia with Negative Family History: Implications from Two Cases of Early-Onset Alzheimer's Disease with De Novo PSEN1 Mutation. , 2019, Journal of Alzheimer's disease : JAD.

[35]  C. Jack,et al.  Association between white matter hyperintensities, cortical volumes, and late-onset epilepsy , 2019, Neurology.

[36]  P. Calabresi,et al.  Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology , 2019, Neurobiology of Aging.

[37]  Dan J Stein,et al.  Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2019, The Lancet Neurology.

[38]  I. Nelken,et al.  Tau impairs neural circuits, dominating amyloid-β effects, in Alzheimer models in vivo , 2018, Nature Neuroscience.

[39]  G. Krauss,et al.  Association Between Midlife Risk Factors and Late-Onset Epilepsy: Results From the Atherosclerosis Risk in Communities Study , 2018, JAMA neurology.

[40]  H. Tanila,et al.  Increased cortical beta power and spike-wave discharges in middle-aged APP/PS1 mice , 2018, Neurobiology of Aging.

[41]  D. Ffytche,et al.  Amyloid-β and Parkinson’s disease , 2018, Journal of Neurology.

[42]  C. Cantoni,et al.  Epileptic seizures in autosomal dominant forms of Alzheimer’s disease , 2018, Seizure.

[43]  Y. Koike,et al.  Incidence of dementia in patients with adult-onset epilepsy of unknown causes , 2018, Journal of the Neurological Sciences.

[44]  S. Maeda,et al.  Neuronal levels and sequence of tau modulate the power of brain rhythms , 2018, Neurobiology of Disease.

[45]  The Lancet Neurology.  Response to the growing dementia burden must be faster , 2018, The Lancet Neurology.

[46]  P. Calabresi,et al.  Selective basal ganglia vulnerability to energy deprivation: Experimental and clinical evidences , 2018, Progress in Neurobiology.

[47]  C. Jack,et al.  Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting , 2018, JAMA neurology.

[48]  Benedikt Zott,et al.  What Happens with the Circuit in Alzheimer's Disease in Mice and Humans? , 2018, Annual review of neuroscience.

[49]  H. Tanila,et al.  INCREASED CORTICAL BETA POWER AND SPIKE-WAVE DISCHARGES IN MIDDLE-AGED APP/PS1 MICE , 2018, Alzheimer's & Dementia.

[50]  N. Garg,et al.  Cracking novel shared targets between epilepsy and Alzheimer’s disease: need of the hour , 2018, Reviews in the neurosciences.

[51]  P. Calabresi,et al.  Late onset epilepsy and Alzheimer's disease: exploring the dual pathogenic role of amyloid-β. , 2018, Brain : a journal of neurology.

[52]  M. Husain,et al.  Reply: Late onset epilepsy and Alzheimer's disease: exploring the dual pathogenic role of amyloid-β. , 2018, Brain : a journal of neurology.

[53]  P. Calabresi,et al.  Liverpool Adverse Events Profile: Italian validation and predictive value for dropout from antiepileptic treatment in people with epilepsy , 2018, Epilepsy & Behavior.

[54]  Masud Husain,et al.  Cognition and dementia in older patients with epilepsy , 2018, Brain : a journal of neurology.

[55]  P. Calabresi,et al.  Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events? , 2018, Cephalalgia : an international journal of headache.

[56]  Robin S. B. Williams,et al.  Valproic acid and its congener propylisopropylacetic acid reduced the amount of soluble amyloid-β oligomers released from 7PA2 cells , 2018, Neuropharmacology.

[57]  Hui Zheng,et al.  Practical considerations for choosing a mouse model of Alzheimer’s disease , 2017, Molecular Neurodegeneration.

[58]  A. Nuñez,et al.  Seizure susceptibility in the APP/PS1 mouse model of Alzheimer’s disease and relationship with amyloid β plaques , 2017, Brain Research.

[59]  Alzheimer's Disease Neuroimaging Initiative,et al.  Amyloid pathology in the progression to mild cognitive impairment , 2017, Neurobiology of Aging.

[60]  S. A. Neymotin,et al.  Tau and amyloid-related pathologies in the entorhinal cortex have divergent effects in the hippocampal circuit , 2017, Neurobiology of Disease.

[61]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[62]  S. Helin,et al.  Brain glucose metabolism and its relation to amyloid load in middle-aged adults with childhood-onset epilepsy , 2017, Epilepsy Research.

[63]  O. Kawakami,et al.  Is adult onset epilepsy of unknown cause a predictor of Alzheimer disease? , 2017, Journal of the Neurological Sciences.

[64]  A. Konnerth,et al.  BACE inhibition-dependent repair of Alzheimer’s pathophysiology , 2017, Proceedings of the National Academy of Sciences.

[65]  B. Dworetzky,et al.  Recurrent Epileptic Auras As a Presenting Symptom of Alzheimer’s Disease , 2017, Front. Neurol..

[66]  Joanne S. Robertson,et al.  Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness , 2017, Alzheimer's & dementia.

[67]  J. Holroyd-Leduc,et al.  The association between dementia and epilepsy: A systematic review and meta‐analysis , 2017, Epilepsia.

[68]  S. Strittmatter,et al.  Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity. , 2017, Cold Spring Harbor perspectives in medicine.

[69]  J. Rinne,et al.  Association Between Childhood-Onset Epilepsy and Amyloid Burden 5 Decades Later , 2017, JAMA neurology.

[70]  T. Tokuda,et al.  Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer’s disease , 2017, PloS one.

[71]  K. Vossel,et al.  Epileptic activity in Alzheimer's disease: causes and clinical relevance , 2017, The Lancet Neurology.

[72]  R. Wong,et al.  Early-Onset Network Hyperexcitability in Presymptomatic Alzheimer’s Disease Transgenic Mice Is Suppressed by Passive Immunization with Anti-Human APP/Aβ Antibody and by mGluR5 Blockade , 2017, Front. Aging Neurosci..

[73]  William J Jagust,et al.  Hippocampal activation is associated with longitudinal amyloid accumulation and cognitive decline , 2017, eLife.

[74]  L. Schneider.  Alzheimer's disease and other dementias: update on research , 2017, The Lancet Neurology.

[75]  E. Carbone,et al.  Early Alterations of Hippocampal Neuronal Firing Induced by Abeta42 , 2016, Cerebral cortex.

[76]  John Collinge,et al.  Structural Variation in Amyloid-β Fibrils from Alzheimer’s Disease Clinical Subtypes , 2016, Nature.

[77]  Heidi E Kirsch,et al.  Incidence and impact of subclinical epileptiform activity in Alzheimer's disease , 2016, Annals of neurology.

[78]  Nick C Fox,et al.  Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer’s disease: a case series , 2016, The Lancet Neurology.

[79]  P. Calabresi,et al.  Epilepsy, amyloid-β, and D1 dopamine receptors: a possible pathogenetic link? , 2016, Neurobiology of Aging.

[80]  L. Mucke,et al.  Network abnormalities and interneuron dysfunction in Alzheimer disease , 2016, Nature Reviews Neuroscience.

[81]  Jia Liu,et al.  Treatment of epilepsy for people with Alzheimer's disease. , 2016, The Cochrane database of systematic reviews.

[82]  Nick C Fox,et al.  Hyperphosphorylated tau in patients with refractory epilepsy correlates with cognitive decline: a study of temporal lobe resections. , 2016, Brain : a journal of neurology.

[83]  J. Pariente,et al.  Seizures in dominantly inherited Alzheimer disease , 2016, Neurology.

[84]  Chao Lu,et al.  Retrospective study , 2016, Medicine.

[85]  H. Tanila,et al.  Increased Epileptiform EEG Activity and Decreased Seizure Threshold in Arctic APP Transgenic Mouse Model of Alzheimer's Disease. , 2016, Current Alzheimer research.

[86]  S. Lipton,et al.  Levetiracetam inhibits oligomeric A&bgr;-induced glutamate release from human astrocytes , 2016, Neuroreport.

[87]  K. Blennow,et al.  Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases—From pathophysiology to clinical practice , 2016, Movement disorders : official journal of the Movement Disorder Society.

[88]  Philip S. Insel,et al.  Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology , 2016, Neurology.

[89]  Jennifer D. Davis,et al.  Cognitive impairment in older adults with epilepsy: Characterization and risk factor analysis , 2016, Epilepsy & Behavior.

[90]  Anselm H. C. Horn,et al.  Amyloid-β dimers in the absence of plaque pathology impair learning and synaptic plasticity. , 2016, Brain : a journal of neurology.

[91]  Shaomin Li,et al.  Soluble Aβ oligomers impair hippocampal LTP by disrupting glutamatergic/GABAergic balance , 2016, Neurobiology of Disease.

[92]  Korey Kam,et al.  Interictal spikes during sleep are an early defect in the Tg2576 mouse model of β-amyloid neuropathology , 2016, Scientific Reports.

[93]  W. M. van der Flier,et al.  Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden. , 2015, Journal of Alzheimer's disease : JAD.

[94]  Zeina N Chemali,et al.  Clinical and Neurophysiologic Characteristics of Unprovoked Seizures in Patients Diagnosed With Dementia. , 2015, The Journal of neuropsychiatry and clinical neurosciences.

[95]  S. Ovsepian,et al.  Neuronal activity and amyloid plaque pathology: an update. , 2015, Journal of Alzheimer's disease : JAD.

[96]  Yung-Yang Lin,et al.  Incidence and risk of seizures in Alzheimer's disease: A nationwide population-based cohort study , 2015, Epilepsy Research.

[97]  Lief E. Fenno,et al.  Chronic optogenetic activation augments Aβ pathology in a mouse model of Alzheimer disease , 2022 .

[98]  Keith A. Vossel,et al.  Tau reduction prevents A-induced axonal transport deficits by blocking activation of GSK 3 , 2015 .

[99]  S. Strittmatter,et al.  Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer’s disease mouse model , 2015, Alzheimer's Research & Therapy.

[100]  H. Tanila,et al.  Reduction of epileptiform activity by valproic acid in a mouse model of Alzheimer's disease is not long-lasting after treatment discontinuation , 2015, Epilepsy Research.

[101]  A. West,et al.  Nitric Oxide Signaling Is Recruited As a Compensatory Mechanism for Sustaining Synaptic Plasticity in Alzheimer's Disease Mice , 2015, The Journal of Neuroscience.

[102]  W. Sobaniec,et al.  Study of the protective effects of nootropic agents against neuronal damage induced by amyloid-beta (fragment 25–35) in cultured hippocampal neurons , 2015, Pharmacological reports : PR.

[103]  Caroline L. Speck,et al.  Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance , 2015, NeuroImage: Clinical.

[104]  H. A. Born,et al.  Seizures in Alzheimer’s disease , 2015, Neuroscience.

[105]  N. Smith,et al.  Epilepsy in older people , 2015 .

[106]  Shao Li,et al.  Lamotrigine attenuates deficits in synaptic plasticity and accumulation of amyloid plaques in APP/PS1 transgenic mice , 2014, Neurobiology of Aging.

[107]  D. Couper,et al.  Results from the Atherosclerosis Risk in Communities study suggest that low serum magnesium is associated with incident kidney disease , 2014, Kidney international.

[108]  E. Trinka,et al.  Cognitive‐behavioral screening in elderly patients with new‐onset epilepsy before treatment , 2014, Acta neurologica Scandinavica.

[109]  Jinmei Li,et al.  Expression of β-amyloid precursor protein in refractory epilepsy. , 2014, Molecular medicine reports.

[110]  F. LaFerla,et al.  Synergistic effects of amyloid-beta and wild-type human tau on dendritic spine loss in a floxed double transgenic model of Alzheimer's disease , 2014, Neurobiology of Disease.

[111]  G. Bloom.  Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. , 2014, JAMA neurology.

[112]  T. Golde,et al.  Genetic Suppression of Transgenic APP Rescues Hypersynchronous Network Activity in a Mouse Model of Alzeimer's Disease , 2014, The Journal of Neuroscience.

[113]  J. Acharya,et al.  Epilepsy in the elderly: Special considerations and challenges , 2014, Annals of Indian Academy of Neurology.

[114]  B. Sheehan,et al.  A 12-month follow-up study of people with dementia referred to general hospital liaison psychiatry services. , 2013, Age and ageing.

[115]  Hong-Guang Xie,et al.  Antiepileptics Topiramate and Levetiracetam Alleviate Behavioral Deficits and Reduce Neuropathology in APPswe/PS1dE9 Transgenic Mice , 2013, CNS neuroscience & therapeutics.

[116]  A. Vortmeyer,et al.  Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein , 2013, Neuron.

[117]  Heidi E Kirsch,et al.  Seizures and epileptiform activity in the early stages of Alzheimer disease. , 2013, JAMA neurology.

[118]  W. Le,et al.  Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-β pathology in a mouse model of Alzheimer's disease. , 2013, Current Alzheimer research.

[119]  L. Douw,et al.  Levetiracetam improves verbal memory in high-grade glioma patients. , 2013, Neuro-oncology.

[120]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[121]  Keith A. Vossel,et al.  Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model , 2012, Proceedings of the National Academy of Sciences.

[122]  A. Vortmeyer,et al.  Alzheimer Amyloid-β Oligomer Bound to Post-Synaptic Prion Protein Activates Fyn to Impair Neurons , 2012, Nature Neuroscience.

[123]  L. Mucke,et al.  Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. , 2012, Cold Spring Harbor perspectives in medicine.

[124]  Bert Sakmann,et al.  Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer’s disease , 2012, Proceedings of the National Academy of Sciences.

[125]  Amy L. Shelton,et al.  Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment , 2012, Neuron.

[126]  Edward O. Mann,et al.  Inhibitory Interneuron Deficit Links Altered Network Activity and Cognitive Dysfunction in Alzheimer Model , 2012, Cell.

[127]  Elizabeth C Mormino,et al.  Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. , 2012, Archives of neurology.

[128]  Denise C. Park,et al.  &bgr;-Amyloid burden in healthy aging: Regional distribution and cognitive consequences , 2012, Neurology.

[129]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[130]  C. Jack,et al.  Chronic divalproex sodium use and brain atrophy in Alzheimer disease , 2011, Neurology.

[131]  C. Jack,et al.  Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. , 2011, Archives of general psychiatry.

[132]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[133]  Jee Hoon Roh,et al.  Neuronal activity regulates the regional vulnerability to amyloid-β deposition , 2011, Nature Neuroscience.

[134]  H. Tanila,et al.  Spontaneous epileptiform discharges in a mouse model of Alzheimer's disease are suppressed by antiepileptic drugs that block sodium channels , 2011, Epilepsy Research.

[135]  L. Mucke,et al.  Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[136]  G. Juhász,et al.  Different electrophysiological actions of 24- and 72-hour aggregated amyloid-beta oligomers on hippocampal field population spike in both anesthetized and awake rats , 2010, Brain Research.

[137]  J. Trojanowski,et al.  CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease , 2010, Neurology.

[138]  F. Calon,et al.  Widespread deficits in adult neurogenesis precede plaque and tangle formation in the 3xTg mouse model of Alzheimer’s disease , 2010, The European journal of neuroscience.

[139]  Helen Clancy,et al.  Update On Research , 2010 .

[140]  L. Mucke,et al.  Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks , 2010, Nature Neuroscience.

[141]  Rie Teraoka,et al.  A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo , 2010, The Journal of Neuroscience.

[142]  E. Cumbo,et al.  Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease , 2010, Epilepsy & Behavior.

[143]  James B Leverenz,et al.  Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. , 2010, Brain : a journal of neurology.

[144]  Ian Parker,et al.  Calcium Signaling and Amyloid Toxicity in Alzheimer Disease* , 2010, The Journal of Biological Chemistry.

[145]  A. J. Larner,et al.  Epileptic Seizures in AD Patients , 2010, NeuroMolecular Medicine.

[146]  B. Preston,et al.  Case Series , 2010, Toxicologic pathology.

[147]  I. Slutsky,et al.  Amyloid-β as a positive endogenous regulator of release probability at hippocampal synapses , 2009, Nature Neuroscience.

[148]  Hyunmi Choi,et al.  Seizures in Alzheimer disease: who, when, and how common? , 2009, Archives of neurology.

[149]  L. Mucke,et al.  Epilepsy and cognitive impairments in Alzheimer disease. , 2009, Archives of neurology.

[150]  Sylvain Rheims,et al.  Amyloid β-Induced Neuronal Hyperexcitability Triggers Progressive Epilepsy , 2009, The Journal of Neuroscience.

[151]  John W. Gilbert,et al.  Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.

[152]  R. Petersen,et al.  Recurrent seizures in patients with dementia: Frequency, seizure types, and treatment outcome , 2009, Epilepsy & Behavior.

[153]  P. Calabresi,et al.  Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies , 2008, Biological Psychiatry.

[154]  Arthur Konnerth,et al.  Clusters of Hyperactive Neurons Near Amyloid Plaques in a Mouse Model of Alzheimer's Disease , 2008, Science.

[155]  Ilya Bezprozvanny,et al.  Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease , 2008, Trends in Neurosciences.

[156]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[157]  C. Rowe,et al.  Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[158]  G. Waldemar,et al.  Atypical early-onset Alzheimer's disease caused by the Iranian APP mutation , 2008, Journal of Neurological Sciences.

[159]  A. Korczyn.  The amyloid cascade hypothesis , 2008, Alzheimer's & Dementia.

[160]  Guojun Bu,et al.  Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In Vivo , 2008, Neuron.

[161]  P. Calabresi,et al.  Levetiracetam monotherapy in Alzheimer patients with late‐onset seizures: a prospective observational study , 2007, European journal of neurology.

[162]  Anatol C. Kreitzer,et al.  Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease , 2007, Neuron.

[163]  Roger M. Nitsch,et al.  Intracellular Aβ and cognitive deficits precede β-amyloid deposition in transgenic arcAβ mice , 2007, Neurobiology of Aging.

[164]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[165]  D. Marson,et al.  Cognitive functioning over 3 years in community dwelling older adults with chronic partial epilepsy , 2007, Epilepsy Research.

[166]  J. Naegele.  Neuroprotective Strategies to Avert Seizure‐Induced Neurodegeneration in Epilepsy , 2007, Epilepsia.

[167]  Z. Matkovic,et al.  The Liverpool Adverse Events Profile: Relation to AED Use and Mood , 2007, Epilepsia.

[168]  K. Rockwood,et al.  Epilepsy and antiepileptic drug use in elderly people as risk factors for dementia , 2007, Journal of the Neurological Sciences.

[169]  M. Canevini,et al.  Elderly People and Epilepsy: Cognitive Function , 2006, Epilepsia.

[170]  Florence Pasquier,et al.  Phenotype associated with APP duplication in five families. , 2006, Brain : a journal of neurology.

[171]  P. Calabresi,et al.  A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine–acetylcholine synaptic balance , 2006, The Lancet Neurology.

[172]  D. Lozsádi,et al.  Prevalence and Causes of Seizures at the Time of Diagnosis of Probable Alzheimer’s Disease , 2006, Dementia and Geriatric Cognitive Disorders.

[173]  A. Hofman,et al.  Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study , 2006, The Lancet Neurology.

[174]  Yaakov Stern,et al.  Incidence and Predictors of Seizures in Patients with Alzheimer's Disease , 2006, Epilepsia.

[175]  Mark Bowlby,et al.  Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[176]  D. Marson,et al.  Older adults with epilepsy demonstrate cognitive impairments compared with patients with amnestic mild cognitive impairment , 2006, Epilepsy & Behavior.

[177]  M. Doran,et al.  Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin–1 gene , 2006, Journal of Neurology.

[178]  M. Menéndez.  Down syndrome, Alzheimer's disease and seizures , 2005, Brain and Development.

[179]  F. Gilliam,et al.  Cognitive Functioning in Community Dwelling Older Adults with Chronic Partial Epilepsy , 2005, Epilepsia.

[180]  J. Hardy,et al.  An African American family with early-onset Alzheimer disease and an APP (T714I) mutation , 2005, Neurology.

[181]  Sumanta Banerjee.  Need of the Hour , 2004 .

[182]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[183]  L. Mucke,et al.  Fyn Kinase Modulates Synaptotoxicity, But Not Aberrant Sprouting, in Human Amyloid Precursor Protein Transgenic Mice , 2004, The Journal of Neuroscience.

[184]  Joanna L. Jankowsky,et al.  Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase , 2004 .

[185]  D. Selkoe,et al.  Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.

[186]  R. Malinow,et al.  APP Processing and Synaptic Function , 2003, Neuron.

[187]  F. Volkmar.  What is a "placebo controlled" study? , 2001, Journal of autism and developmental disorders.

[188]  M. Brodie,et al.  Cognitive effects of anticonvulsant monotherapy in elderly patients: a placebo-controlled study , 1998, Seizure.

[189]  H. Braak,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[190]  M. Bobinski,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[191]  A. Hofman,et al.  Risk of dementia in patients with Parkinson's disease, epilepsy, and severe head trauma: a register-based follow-up study. , 1995, American journal of epidemiology.

[192]  D. Borchelt,et al.  Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins , 1995, Neuron.

[193]  L. Volicer,et al.  Effect of seizures on progression of dementia of the Alzheimer type. , 1995, Dementia.

[194]  M. Mattson,et al.  Anticonvulsants attenuate amyloid β-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology , 1995, Neurobiology of Aging.

[195]  G. Fenton,et al.  Epileptic Seizures in Elderly Patients with Dementia , 1992, Epilepsia.

[196]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[197]  D J Ballard,et al.  Clinical risk factors for Alzheimer's disease , 1991, Neurology.

[198]  Anthony F Jorm,et al.  A case‐control study of Alzheimer's disease in Australia , 1990, Neurology.

[199]  J. Morris,et al.  Advanced Alzheimer's disease is a risk factor for late-onset seizures. , 1990, Archives of neurology.

[200]  A. Hofman,et al.  History of dementia and Parkinson's disease in 1st‐degree relatives of patients with Alzheimer's disease , 1989, Neurology.

[201]  E L Baker,et al.  Risk factors for Alzheimer's disease , 1987, Neurology.

[202]  W. Hauser,et al.  Seizures and myoclonus in patients with Alzheimer's disease , 1986, Neurology.

[203]  L M Schuman,et al.  A case-control study of dementia of the Alzheimer type. , 1985, American journal of epidemiology.

[204]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[205]  B. Mcwilliams,et al.  Cognitive Function , 2021, Encyclopedia of Gerontology and Population Aging.

[206]  Jürgen Götz,et al.  Amyloid-β and tau complexity — towards improved biomarkers and targeted therapies , 2018, Nature Reviews Neurology.

[207]  A. Szűcs,et al.  Sleep EEG Detects Epileptiform Activity in Alzheimer's Disease with High Sensitivity. , 2017, Journal of Alzheimer's disease : JAD.

[208]  E. Beghi,et al.  Adult-Onset Epilepsy in Presymptomatic Alzheimer's Disease: A Retrospective Study. , 2017, Journal of Alzheimer's disease : JAD.

[209]  Marta Elena Losa-Iglesias,et al.  Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.

[210]  M. Gossop,et al.  Association between depression and enterovirus infection A nationwide population-based cohort study , 2017 .

[211]  B. Cretin,et al.  Epileptic Prodromal Alzheimer's Disease, a Retrospective Study of 13 New Cases: Expanding the Spectrum of Alzheimer's Disease to an Epileptic Variant? , 2016, Journal of Alzheimer's disease : JAD.

[212]  Qian Zhu,et al.  Lamotrigine Reduces β-Site AβPP-Cleaving Enzyme 1 Protein Levels Through Induction of Autophagy. , 2015, Journal of Alzheimer's disease : JAD.

[213]  J. Trojanowski,et al.  Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. , 2015, Journal of Alzheimer's disease : JAD.

[214]  Reisa A. Sperling,et al.  Alzheimer's disease , 2015, Nature Reviews Disease Primers.

[215]  Maja O’Connor.  LONGITUDINAL STUDY , 2013 .

[216]  J. Stevens,et al.  The Atherosclerosis Risk in Communities Study , 2013 .

[217]  P. Rossini,et al.  Cortical sources of resting state EEG rhythms are sensitive to the progression of early stage Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[218]  Vinh Q Nguyen,et al.  Down syndrome and dementia: seizures and cognitive decline. , 2012, Journal of Alzheimer's disease : JAD.

[219]  C. Opazo,et al.  Soluble Aβ(1-40) peptide increases excitatory neurotransmission and induces epileptiform activity in hippocampal neurons. , 2011, Journal of Alzheimer's disease : JAD.

[220]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[221]  A. Bacci,et al.  Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease , 2011, Nature Neuroscience.

[222]  J. Malter,et al.  Seizure susceptibility and mortality in mice that over-express amyloid precursor protein. , 2008, International journal of clinical and experimental pathology.

[223]  A. Hofman,et al.  a prospective case-cohort study , 2006 .

[224]  A. Vikat,et al.  A Register-Based Follow-up Study of Marriages in 1981- 1998 , 2005 .

[225]  M. Mendez,et al.  Seizures in Elderly Patients with Dementia , 2003, Drugs & aging.

[226]  E. Perucca,et al.  Pharmacological and Therapeutic Properties of Valproate , 2002, CNS drugs.

[227]  A. Kolivras,et al.  Epidemiology and management , 2002 .

[228]  J. Williams,et al.  IN A POPULATION-BASED CASE-CONTROL STUDY , 2001 .

[229]  C. Hong,et al.  Risk factors for Alzheimer's disease: a case-control study. , 1997, Neuroepidemiology.

[230]  A Hofman,et al.  Clinical features and mortality in patients with early-onset Alzheimer's disease. , 1996, European neurology.

[231]  R. Stelzmann,et al.  An english translation of alzheimer's 1907 paper, “über eine eigenartige erkankung der hirnrinde” , 1995, Clinical anatomy.

[232]  L. Fratiglioni,et al.  Medical history and the risk of Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. , 1991, International journal of epidemiology.

[233]  K. Johnson.  An Update. , 1984, Journal of food protection.